It is the active metabolite of irinotecan （an analog of camptothecin - a topoisomerase I inhibitor） but has 1000 times more activity than irinotecan itself.
In vitro cytotoxicity assays show that the potency of SN-38 relative to irinotecan varies from 2- to 2000-fold.
SN38 is formed via hydrolysis of irinotecan by carboxylesterases and metabolized via glucuronidation by UGT1A1.
The variant of UGT1A1 in ～10％ of Caucasians which leads to poor metabolism of SN-38 predicts irinotecan toxicity, as it is then less easily excreted from the body in its SN-38 glucuronide form.
SN-38 and its glucuronide are lost into the bile and intestines.
It can cause the symptoms of diarrhoea and myelosuppression experienced by ～25％ of the patients administered irinotecan.
仕様
容量：100ug
Source：Monoclonal Anti-SN38 Antibody, is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with SN38.
